Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aramchol Phase IIa in NAFLD/NASH
NCT01094158Phase 2Completed
- Sponsor
- Galmed Pharmaceuticals
- Start
- Nov 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aramchol in non-alcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), sponsored by Galmed Pharmaceuticals. Started Nov 2010; status: completed.
02
Drugs
aramchol
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT01094158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01094158.